Prior selection of itraconazole in the treatment of recalcitrant Trichophyton indotineae infection: Real‐world results from retrospective analysis

Abstract

AbstractBackgroundThe number of terbinafine‐resistant Trichophyton indotineae is increasing in recent years while the treatment is still a matter to discuss.ObjectivesTo explore the best therapeutic approach, we present real‐world treatment of T. indotineae infection by analysing publicly available data.MethodsWe have reviewed all published articles, mainly including case reports and case series, on the drug‐resistant T. mentagrophytes complex by using the key search terms to search the databases.ResultsWe enrolled 25 articles from 14 countries, including 203 times of treatment information for 113 patients. The cure rate of itraconazole 200 mg per day at the fourth, eighth and the twelfth week were 27.27%, 48.48% and 54.55%, respectively, which was significantly higher than terbinafine 250 mg per day (8.77%, 24.56% and 28.07%) and even 500 mg/d terbinafine. Griseofulvin 500–1000 mg for 2–6 months may be effective while fluconazole had no record of successful treatment. Voriconazole and ravuconazole had potential therapeutic efficacy. Topical therapy alone showed limited therapeutic efficacy, but the combination with oral antifungals can be alternative.ConclusionOral itraconazole 200 mg per day for 4–8 weeks was the most effective treatment out of these commonly used antifungal drugs, and can be prior selection.